ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 140 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,969 | -44.3% | 2,819 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $26,865 | +39.1% | 2,819 | +60.5% | 0.00% | 0.0% |
| Q1 2023 | $19,316 | -47.1% | 1,756 | -28.8% | 0.00% | -50.0% |
| Q4 2022 | $36,497 | -22.6% | 2,466 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $47,125 | +3.9% | 2,466 | +15.8% | 0.00% | 0.0% |
| Q2 2022 | $45,369 | +38.2% | 2,129 | +24.9% | 0.00% | +100.0% |
| Q1 2022 | $32,838 | -79.9% | 1,705 | -78.3% | 0.00% | -50.0% |
| Q4 2021 | $163,328 | -13.2% | 7,875 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $188,134 | -12.5% | 7,875 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $214,909 | +31.2% | 7,875 | +39.1% | 0.00% | +50.0% |
| Q1 2021 | $163,744 | +2.8% | 5,660 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $159,216 | -4.0% | 5,660 | 0.0% | 0.00% | -33.3% |
| Q3 2020 | $165,838 | +45.2% | 5,660 | +49.9% | 0.00% | +50.0% |
| Q2 2020 | $114,216 | +1.5% | 3,777 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $112,555 | – | 3,777 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |